Evidence map›Paper›PMID 33765507›Full record

ArticleEpilepsy research2021

Analysis of intraoperative human brain tissue transcriptome reveals putative risk genes and altered molecular pathways in glioma-related seizures.

Anteneh M Feyissa, Anna Carrano, Xue Wang, Mariet Allen, Nilüfer Ertekin-Taner, Dennis W Dickson, Mark E Jentoft, Steven S Rosenfeld, William O Tatum, Anthony L Ritaccio and 2 more

Open access · greenAbstract read
In one paragraph

Article in Epilepsy research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Anteneh M FeyissaDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: Feyissa.Anteneh@mayo.edu.
Anna CarranoDepartment of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA.
Xue WangDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Mariet AllenDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Nilüfer Ertekin-TanerDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Dennis W DicksonDepartment of Pathology, Mayo Clinic, Jacksonville, FL, USA.
Mark E JentoftDepartment of Pathology, Mayo Clinic, Jacksonville, FL, USA.
Steven S RosenfeldDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA; Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA; Department of Pharmacology, Mayo Clinic, Jacksonville, FL, USA.
William O TatumDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Anthony L RitaccioDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Hugo Guerrero-CázaresDepartment of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA. Electronic address: Cazares.Hugo@mayo.edu.
Alfredo Quiñones-HinojosaDepartment of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA. Electronic address: Quinones-Hinojosa.Alfredo@mayo.edu.
WinnMed · USJacksonville College · US

Funding

Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.U01AG046139 · NIA · UNIVERSITY OF FLORIDA · PI ERTEKIN-TANER, NILUFER, FUNK, CORY · 2013 to 2022
$24.6M
Integrative translational discovery of vascular risk factors in aging and dementiaRF1AG051504 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN, ERTEKIN-TANER, NILUFER · 2015 to 2019
$9.8M
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in ADR01AG061796 · NIA · MAYO CLINIC JACKSONVILLE · PI ERTEKIN-TANER, NILUFER · 2018 to 2022
$5.7M
Intra-Operative, Label-Free Detection of Brain Cancer Infiltration with Quantitative Optical ImagingR01CA200399 · NCI · JOHNS HOPKINS UNIVERSITY · PI LI, XINGDE, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$3.0M
Targeting Go and Grow in GlioblastomaR01NS118513 · NINDS · MAYO CLINIC JACKSONVILLE · PI CANOLL, PETER, KENCHAPPA, RAJAPPA · 2020 to 2024
$2.8M
A novel microfluidic device to predict brain cancer prognosis and response to therapyR01CA216855 · NCI · MAYO CLINIC JACKSONVILLE · PI KONSTANTOPOULOS, KONSTANTINOS, QUINONES-HINOJOSA, ALFREDO · 2018 to 2022
$2.4M
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)R01CA195503 · NCI · MAYO CLINIC JACKSONVILLE · PI GREEN, JORDAN, QUINONES-HINOJOSA, ALFREDO · 2016 to 2020
$1.9M
BMP4 Engineered Mesenchymal Stem Cell Therapy for GlioblastomaR01CA183827 · NCI · MAYO CLINIC JACKSONVILLE · PI QUINONES-HINOJOSA, ALFREDO · 2015 to 2019
$1.9M
Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapyR43CA221490 · NCI · CELL REPROGRAMMING AND THERAPEUTICS, LLC · PI ALEXANIAN, ARSHAK R, QUINONES-HINOJOSA, ALFREDO · 2018 to 2018
$300k
NCI NIH HHS R01 CA183827NCI NIH HHS R01 CA195503NCI NIH HHS R01 CA200399NCI NIH HHS R01 CA216855NCI NIH HHS R43 CA221490NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG061796NIA NIH HHS RF1 AG051504NIA NIH HHS U01 AG046139NINDS NIH HHS R01 NS118513
6 · The paper itself

Abstract

backgroundThe pathogenesis of glioma-related seizures (GRS) is poorly understood. Here in, we aim to identify putative molecular pathways that lead to the development of GRS.

methodsWe determined brain transcriptome from intraoperative human brain tissue of patients with either GRS, glioma without seizures (non-GRS), or with idiopathic temporal lobe epilepsy (iTLE). We performed transcriptome-wide comparisons between disease groups tissue from non-epileptic controls (non-EC) to identify differentially-expressed genes (DEG). We compared DEGs to identify those that are specific or common to the groups. Through a gene ontology analysis, we identified molecular pathways enriched for genes with a Log-fold change ≥1.5 or ≤-1.5 and p-value <0.05 compared to non-EC.

resultsWe identified 110 DEGs that are associated with GRS vs. non-GRS: 80 genes showed high and 30 low expression in GRS. There was significant overexpression of genes involved in cell-to-cell and glutamatergic signaling (CELF4, SLC17A7, and CAMK2A) and down-regulation of genes involved immune-trafficking (CXCL8, H19, and VEGFA). In the iTLE vs GRS analysis, there were 1098 DEGs: 786 genes were overexpressed and 312 genes were underexpressed in the GRS samples. There was significant enrichment for genes considered markers of oncogenesis (GSC, MYBL2, and TOP2A). Further, there was down-regulation of genes involved in the glutamatergic neurotransmission (vesicular glutamate transporter-2) in the GRS vs. iTLE samples.

conclusionsWe identified a number of altered processes such as cell-to-cell signaling and interaction, inflammation-related, and glutamatergic neurotransmission in the pathogenesis of GRS. Our findings offer a new landscape of targets to further study in the fields of brain tumors and seizures.

Indexed as

GliomaSeizuresTranscriptomeBrainComputational BiologyGene Expression ProfilingHumansBrain tumor-related epilepsyCytokinesEpileptogenesisGlioma-related seizuresGlutamatergic signalingImmune-traffickingVesicular glutamate transporter

Identifiers

PMID33765507
PMCPMC9356713
OpenAlexW3138638334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.